The effect of melatonin on experimentally-induced myringosclerosis in rats

Year 2010, Volume: 20 Issue: 6, 299 - 304, 20.12.2010

Kadir Çağdaş Kazıkdaş Ensari Güneli Kazım Tuğyan Güven Erbil Tuncay Küme Nazan Uysal Osman Yılmaz Mustafa Bülent Şerbetçioğlu

Abstract

Objectives: This study determined the preventive effect of melatonin on the occurrence of experimentally-induced myringosclerosis of the tympanic membrane TM . Materials and Methods: Twenty Wistar albino-type rats weighing approximately 300 g each were randomly separated into two groups and myringotomized on the left TMs: group 1 rats n=6 received intraperitoneal melatonin injections 10 mg/kg/day whereas group 2 rats n=12 were treated with physiological serum only. The remaining two rats were served as the control group for histological comparison and standardization. After 15 days of treatment, myringotomized membranes were examined by otomicroscopy and harvested for histopathological evaluation. The functional effect of myringosclerotic plaques in the TMs of the two groups were compared with tympanometric measurements. Results: Tympanic membranes in group 2 revealed extensive myringosclerotic plaques, on the other hand, TMs in group 1 showed faint or no existence of myringosclerosis. The mean magnitude of the maximum admittance from group 2 measured by tympanometry reduced to about 40% of the values obtained from group 1 Z=–2,067, p=0.041 . The mean magnitude of the maximum admittance from melatonin group was very close to the mean tympanometric value of non-myringotomized Wistar albino rats, demonstrating a functional outcome. Conclusion: The occurrence of myringosclerosis following experimental myringotomy can be hindered by systemic melatonin treatment.

Keywords

Experimental, melatonin, myringosclerosis, tympanogram

Sıçanlarda deneysel olarak oluşturulan miringosklerozda melatoninin etkisi

Abstract

Amaç: Bu çalışmada melatonin uygulamasının, timpanik membran TM ’larda deneysel olarak meydana getirilen miringosklerozun oluşumunu engelleyici etkisi araştırıldı.Gereç ve Yöntemler: Herbiri yaklaşık 300 g olan 20 adet Wistar albino cinsi sıçan randomize olarak iki gruba ayrıldı ve sol taraf TM’lerine miringotomi uygulandı: Grup 1 sıçanlara n=6 10 mg/kg/gün intraperitoneal melatonin injeksiyonu yapıldı, grup 2 sıçanlara n=12 ise sadece serum fizyolojik uygulandı. Geriye kalan iki sıçan ise histolojik karşılaştırma ve standardizasyon amacıyla kontrol grubu olarak ayrıldı. On beş günlük tedavi süresinin sonunda miringotomi uygulanan membranlar otomikroskopik olarak incelendi ve histopatolojik inceleme için ayrıldı. Her iki gruptaki miringosklerotik plakların TM’ler üzerine fonksiyonel etkisi timpanometrik ölçümlerle karşılaştırıldı.Bulgular: Grup 2’deki TM’lerde miringosklerotik plaklar yaygın bir şekilde izlenirken, diğer yandan grup 1’deki TM’lerde miringoskleroz ya hafif izlendi ya da hiç izlenmedi. Timpanometrik ölçümler ile grup 2’de elde edilen ortalama maksimum admitans değeri, grup 1’e göre yaklaşık %40 düşük idi Z=–2,067, p=0.041 . Melatonin grubunda ölçülen ortalama maksimum admitans değeri miringotomi uygulanmamış, normal Wistar albino sıçanların standart ortalama timpanometrik değerlerine çok yakındır ve fonksiyonel bir sonuç ifade etmektedir.Sonuç: Deneysel miringotomi sonrasında izlenen miringoskleroz oluşumu sistemik melatonin tedavisi ile engellenebilir

Keywords

Deneysel, melatonin, miringoskleroz, timpanogram

References

• Mattsson C, Magnuson K, Hellström S. Myringotomy: a prerequisite for the development of myringosclero- sis? Laryngoscope 1998;108:102-6.
• Koç A, Uneri C. Genetic predisposition for tympa- nosclerotic degeneration. Eur Arch Otorhinolaryngol 2002;259:180-3.
• Mattsson C, Marklund SL, Hellström S. Application of oxygen free radical scavengers to diminish the occur- rence of myringosclerosis. Ann Otol Rhinol Laryngol 1997;106:513-8.
• Ozcan C, Görür K, Cinel L, Talas DU, Unal M, Cinel I. The inhibitory effect of topical N-acetylcysteine application on myringosclerosis in perforated rat tym- panic membrane. Int J Pediatr Otorhinolaryngol 2002; 63:179-84.
• Polat S, Oztürk O, Uneri C, Yüksel M, Haklar G, Bozkurt S, et al. Determination of reactive oxygen spe- cies in myringotomized tympanic membranes: effect of vitamin e treatment. Laryngoscope 2004;114:720-5.
• Emir H, Kaptan ZK, Samim E, Sungu N, Ceylan K, Ustun H. The preventive effect of ginkgo biloba extract in myringosclerosis: study in rats. Otolaryngol Head Neck Surg 2009;140:171-6.
• Reiter RJ, Tan DX, Mayo JC, Sainz RM, Leon J, Czarnocki Z. Melatonin as an antioxidant: biochemi- cal mechanisms and pathophysiological implications in humans. Acta Biochim Pol 2003;50:1129-46.
• Tan DX, Reiter RJ, Manchester LC, Yan MT, El-Sawi M, Sainz RM, et al. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem 2002;2:181-97.
• Mattsson C, Stierna P, Hellström S. Treatment with dexamethasone arrests the development of myringo- sclerosis after myringotomy. Am J Otol 2000;21:804-8.
• Kazikdas KC, Uguz MZ, Erbil G, Tugyan K, Yilmaz O, Guneli E, et al. The anti-oxidant effect of alpha-tocoph- erol in the prevention of experimentally induced myringosclerosis. Otol Neurotol 2006;27:882-6.
• Cagdas KK. The role of experimental myringosclerosis in interpretation of tympanograms and its possible clinical implications. Med Hypotheses 2005;64:1132-4.
• Mattsson C, Magnuson K, Hellström S. Myringosclerosis caused by increased oxygen concentration in trauma- tized tympanic membranes. Experimental study. Ann Otol Rhinol Laryngol 1995;104:625-32.
• Spratley JE, Hellström SO, Mattsson CK, Pais-Clemente M. Topical ascorbic acid reduces myringosclerosis in perforated tympanic membranes. A study in the rat. Ann Otol Rhinol Laryngol 2001;110:585-91.
• Yildirim I, Ciralik H, Okur E, Aydoğan B, Kiliç MA. The effect of intraperitoneal administration of zinc aspartate on myringosclerosis in perforated tympanic membranes of rats. Kulak Burun Bogaz Ihtis Derg 2009;19:263-7.
• Pardridge WM, Mietus LJ. Transport of albumin- bound melatonin through the blood-brain barrier. J Neurochem 1980;34:1761-3.
• Mattsson C, Johansson C, Hellström S. Myringosclerosis develops within 9h of myringotomy. ORL J Otorhinolaryngol Relat Spec 1999;61:31-6.
• Reiter RJ. Oxidative damage in the central nervous system: protection by melatonin. Prog Neurobiol 1998; 56:359-84.
• Jou MJ, Peng TI, Reiter RJ, Jou SB, Wu HY, Wen ST. Visualization of the antioxidative effects of melatonin at the mitochondrial level during oxidative stress- induced apoptosis of rat brain astrocytes. J Pineal Res 2004;37:55-70.
• Skotnicka B, Hassmann E. Proinflammatory and immunoregulatory cytokines in the middle ear effu- sions. Int J Pediatr Otorhinolaryngol 2008;72:13-7.
• Tyagi E, Agrawal R, Nath C, Shukla R. Effect of mela- tonin on neuroinflammation and acetylcholinesterase activity induced by LPS in rat brain. Eur J Pharmacol 2010;640:206-10.
• Carrillo-Vico A, García-Mauriño S, Calvo JR, Guerrero JM. Melatonin counteracts the inhibitory effect of PGE2 on IL-2 production in human lymphocytes via its mt1 membrane receptor. FASEB J 2003;17:755-7.
• von Unge M, Bagger-Sjöbäck D, Borg E. Mechanoacoustic properties of the tympanic mem- brane: a study on isolated Mongolian gerbil temporal bones. Am J Otol 1991;12:407-19.